Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: A retrospective study

Despite the efficacy of shunt surgery in the treatment of variceal bleeding, less effective nonoperative therapies are being substituted because surgical shunt does not modify survival and increases hepatic encephalopathy. However, the real impact of shunt surgery on the natural history of ascites and its complications has not been established. The course of 204 Child‐Pugh A and B cirrhotic patients with variceal bleeding included in three controlled trials of our units who survived first hospitalization was updated. Ninetyeight patients (group I) were treated by portacaval (56 patients) or distal splenorenal (42 patients) shunt, whereas 106 (group II) were treated by nonshunt procedures (sclerotherapy in 89 patients and staple transection in 17 patients). As expected, the 5‐yr probability of variceal rebleeding was lower (13% vs. 44%) and hepatic encephalopathy higher (50% vs. 28%) in group I than in group II, and survival was similar (67% vs. 60%). Shunt surgery had a great impact on the natural history of ascites and its complications. The probability of occurrence of ascites (15% vs. 73%; p < 0.0001), spontaneous bacterial peritonitis (2% vs. 21%; p < 0.0001) and hepatorenal syndrome (4% vs. 21%; p < 0.01) was greatly reduced. These beneficial effects accounted for the lower percentage patients requiring readmissions (51% vs. 70%; p = 0.02) and shorter total time spent in hospital (14 + 22 vs. 26 + 39 days/patient p = 0.01) in group I. These data indicate that shunt surgery, in addition to reducing the probability of rebleeding, markedly decreases the probability of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome development. Therefore, ascites and its complications should be considered in any therapeutic trial assessing the efficacy of surgical or percutaneous portacaval anastomosis on variceal bleeding. (HEPATOLOGY 1994;20:584‐591).

[1]  W. Jiménez,et al.  Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. , 1993, Gastroenterology.

[2]  V. Arroyo,et al.  Renal effects of acute isosorbide‐5‐mononitrate administration in cirrhosis , 1993, Hepatology.

[3]  J. Llach,et al.  Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime , 1993, Hepatology.

[4]  V. Arroyo,et al.  Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. , 1991, The New England journal of medicine.

[5]  E. Cabré,et al.  Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. , 1991, Gastroenterology.

[6]  M. Kutner,et al.  Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis. A prospective, randomized trial. , 1990, Annals of internal medicine.

[7]  O. Traynor,et al.  Should portosystemic shunt be reconsidered in the treatment of intractable ascites in cirrhosis? , 1988, Archives of surgery.

[8]  L. Grande,et al.  Sclerotherapy vs. Distal splenorenal shunt in the elective treatment of variceal hemorrhage: A randomized controlled trial , 1987, Hepatology.

[9]  V. Arroyo,et al.  Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage , 1985, Hepatology.

[10]  J. Hoefs,et al.  Culture‐Negative Neutrocytic Ascites: A Variant of Spontaneous Bacterial Peritonitis , 1984, Hepatology.

[11]  Zahlten Rn Aminopyrine breath test. , 1983 .

[12]  A. J. Donovan,et al.  Results of a 12-year randomized trial of portacaval shunt in patients with alcoholic liver disease and bleeding varices. , 1981, Gastroenterology.

[13]  J. Degos,et al.  A CONTROLLED STUDY OF THERAPEUTIC PORTACAVAL SHUNT IN ALCOHOLIC CIRRHOSIS , 1976, The Lancet.

[14]  M. Kerstein,et al.  The hepatorenal syndrome: recovery after portacaval shunt. , 1975, Annals of surgery.

[15]  T. Chalmers,et al.  A controlled study of the therapeutic portacaval shunt. , 1974, Gastroenterology.

[16]  M. Orloff PATHOGENESIS AND SURGICAL TREATMENT OF INTRACTABLE ASCITES ASSOCIATED WITH ALCOHOLIC CIRRHOSIS * , 1970 .

[17]  P. Numann,et al.  Functional renal failure in cirrhosis. Recovery after portacaval shunt. , 1970, Annals of internal medicine.

[18]  L. Rousselot,et al.  A Seven‐Year Experience with Side‐to‐Side Portacaval Shunt for Cirrhotic Ascites , 1968, Annals of surgery.

[19]  K. Reemtsma,et al.  The portacaval shunt operation in patients with cirrhosis and ascites. , 1960, Surgery.

[20]  M. Kutner,et al.  Distal spleno-renal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. A meta-analysis of 4 randomized clinical trials. , 1992, Journal of hepatology.

[21]  J. Llach,et al.  Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors , 1988, Hepatology.

[22]  D. Trunkey,et al.  Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and acute variceal hemorrhage. Long-term follow-up. , 1987, The New England journal of medicine.

[23]  V. Arroyo,et al.  Compensated cirrhosis: Natural history and prognostic factors , 1987, Hepatology.

[24]  J. Visa,et al.  Randomized trial of portacaval shunt, stapling transection and endoscopic sclerotherapy in uncontrolled variceal bleeding. , 1987, Journal of hepatology.

[25]  H. Smulyan,et al.  Effects of a portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome. , 1979, Kidney international.